{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:11:04Z","timestamp":1753355464523,"version":"3.37.3"},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T00:00:00Z","timestamp":1564531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>The single\u2010arm ROSiA study evaluated frontline bevacizumab for advanced ovarian cancer. We explored how discordant surgically and radiologically assessed postoperative residual disease affects outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>After debulking surgery, 1021 patients received 4 to 8 cycles of carboplatin\u2010paclitaxel plus bevacizumab until progression or up to 24 months. The primary endpoint was safety; progression\u2010free survival (PFS) was a secondary endpoint. We performed post hoc exploratory PFS analyses in four subgroups: surgeon\u2010reported no visible residuum (NVR) without target lesions; surgeon\u2010reported NVR with target lesions; macroscopic (\u22641\u2009cm) residuum; and &gt;1\u2009cm residuum.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Surgical and radiological assessments were concordant in 94% of patients; 61 patients (6%; 21% of those with surgeon\u2010reported NVR) had NVR with target lesions. Median PFS was numerically longest in patients with concordant surgically\/radiologically assessed NVR (35.5 months), intermediate for surgeon\u2010reported NVR with target lesions (31.8 months), and shortest for visible residuum (27.9 and 20.2 months for visible residuum \u22641 and &gt;1\u2009cm, respectively). One\u2010year and 2\u2010year PFS rates showed the same pattern.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These analyses suggest that prognosis is potentially worse in patients with radiologically detected target lesions despite surgeon\u2010reported NVR compared with concordant NVR by both assessment methods. Postsurgical imaging may add valuable prognostic information.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jso.25647","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T04:24:26Z","timestamp":1564633466000},"page":"786-793","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcome according to residual disease (surgeon's report vs pre\u2010chemotherapy imaging) in patients with bevacizumab\u2010treated ovarian cancer: Analysis of the ROSiA study"],"prefix":"10.1002","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0483-4582","authenticated-orcid":false,"given":"Jacob","family":"Korach","sequence":"first","affiliation":[{"name":"Gynecologic Oncology Department Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Hashomer  Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[{"name":"Division of Medical Gynecologic Oncology IEO, European Institute of Oncology IRCCS and University of Milan\u2010Bicocca  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Mendiola","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Hospital Universitario 12 de Octubre  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Selle","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Groupe Hospitalier Diaconesses Croix Saint\u2010Simon and Alliance Pour la Recherche en Canc\u00e9rologie  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Dolado","sequence":"additional","affiliation":[{"name":"Pharma Development Medical Affairs, F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Donica","sequence":"additional","affiliation":[{"name":"Pharma Development Medical Affairs, F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Princess Margaret Hospital, University of Toronto  Toronto ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,7,31]]},"reference":[{"key":"e_1_2_8_1_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.1953"},{"key":"e_1_2_8_1_3_1","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1998.5145"},{"key":"e_1_2_8_1_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3106"},{"key":"e_1_2_8_1_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908806"},{"key":"e_1_2_8_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62223-6"},{"key":"e_1_2_8_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.08.014"},{"key":"e_1_2_8_1_8_1","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/annonc\/mdx010","article-title":"Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors","volume":"28","author":"McGee J","year":"2017","journal-title":"Ann Oncol"},{"key":"e_1_2_8_1_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.2317"},{"key":"e_1_2_8_1_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181d09fd6"},{"key":"e_1_2_8_1_11_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.11.7257"},{"key":"e_1_2_8_1_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31820aed49"},{"key":"e_1_2_8_1_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000836"},{"key":"e_1_2_8_1_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103799"},{"key":"e_1_2_8_1_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"e_1_2_8_1_16_1","unstructured":"Genentech Inc. Bevacizumab Prescribing Information2018.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125085s323lbl.pdf. Accessed December 5 2018."},{"key":"e_1_2_8_1_17_1","unstructured":"Roche Registration Limited. Summary of Product Characteristics.https:\/\/ec.europa.eu\/health\/documents\/community\u2010register\/2017\/20170602137926\/anx_137926_en.pdf. Accessed December 5 2018."},{"key":"e_1_2_8_1_18_1","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1994.1253"},{"key":"e_1_2_8_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.07.123"},{"key":"e_1_2_8_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.03.043"},{"key":"e_1_2_8_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.08.036"},{"key":"e_1_2_8_1_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000365357"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjso.25647","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.25647","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jso.25647","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.25647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T13:12:21Z","timestamp":1694265141000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.25647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,31]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1002\/jso.25647"],"URL":"https:\/\/doi.org\/10.1002\/jso.25647","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"type":"print","value":"0022-4790"},{"type":"electronic","value":"1096-9098"}],"subject":[],"published":{"date-parts":[[2019,7,31]]},"assertion":[{"value":"2019-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}